The Phase 3 HER2CLIMB-05 trial showed a 35.9% reduction in risk for patients treated with TUKYSA
Results from the Phase 2 PHAROS trial potentially establish new benchmark with targeted combination therapies for this patient population
Based on these promising results, Johnson & Johnson plans to move the program into a Phase 3 trial to further investigate subcutaneous amivantamab
Treatment with TUKYSA was well-tolerated, with a safety profile consistent with previously known profiles of the individual agents
BPDCN is a challenging blood cancer with characteristics of both leukemia and lymphoma
This strategic collaboration represents the third clinical trial under Senhwa’s five-year NCI-sponsored cancer research program
he new version features a streamlined sample-to-analysis workflow, built-in HRD detection, faster turnaround, and lower tissue requirements
3SBio will receive a payment of $1.25 billion. Pfizer will also make a $100 million equity investment in 3SBio
Anti-cancer patent now validated in Spain, the UK, and as a Unitary Patent covering multiple EU member states
Vepdegestrant is the first and only PROteolysis TArgeting Chimera (PROTAC) evaluated in a Phase 3 clinical trial and the first to show benefit in patients with breast cancer
Subscribe To Our Newsletter & Stay Updated
